Corbus Bollinger Bands Narrowing, KDJ Death Cross on 15min Chart

On Corbus's 15-minute chart, Bollinger Bands are narrowing and a KDJ Death Cross was triggered at 10:15 on June 6, 2025. This indicates a reduction in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.

Corbus Pharmaceuticals (NASDAQ:CRBP) saw a reduction in its stock price target by Oppenheimer analysts, who lowered it to $53.00 from $60.00 on Tuesday. The stock is currently trading at $12.26, well below the analyst consensus range of $28-$55, with a market capitalization of $150 million Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1].

The price target adjustment comes ahead of Corbus's presentation at the European Society for Medical Oncology (ESMO) conference, scheduled for October 19, 2025. The presentation will focus on results from approximately 100 additional patients treated with Corbus's Nectin-4 targeting ADC, CRB-701, particularly for head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1].

Oppenheimer analysts highlighted the importance of the upcoming ESMO presentation, noting that it represents an opportunity to strengthen both safety and efficacy datasets for CRB-701. The stock has been trading with narrowing Bollinger Bands and a KDJ Death Cross triggered at 10:15 on June 6, 2025, indicating a reduction in price fluctuations and a shift in momentum towards the downside .

In addition to the ESMO presentation, Corbus has received an FDA Fast Track Designation for CRB-701, a Nectin-4-targeting antibody-drug conjugate intended for treating recurrent or metastatic head and neck squamous cell carcinoma Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1]. Corbus will also present updated clinical data from its Phase 1/2 study of CRB-701 at the ESMO Congress in October 2025, covering results from trials involving patients with urothelial and non-urothelial solid tumors Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1]. Furthermore, Corbus has initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity, following the completion of the single ascending dose portion earlier in the year Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data^[1].

These developments highlight Corbus Pharmaceuticals' ongoing efforts in advancing its clinical trials and drug development pipeline.